dbACP: A Comprehensive Database of Anti-Cancer Peptides

dbacp05040

General Description

Peptide name : P18

Source/Organism : Synthetic peptide

Linear/Cyclic : Linear

Chirality : L

Sequence Information

Sequence : KWKLFKKIPKFLHLAKKF

Peptide length: 18

C-terminal modification: Linear

N-terminal modification : Free

Non-natural peptide information: None

Activity Information

Assay type : MTT/MTS assay

Assay time : Not found

Activity : 50 ± 3.09% cell viability at 40 µM

Cell line : M14

Cancer type : Skin cancer

Other activity : Not found

Physicochemical Properties

Amino acid composition bar chart :

Molecular mass : 2300.9155 Dalton

Aliphatic index : 0.922

Instability index : -9.9389

Hydrophobicity (GRAVY) : -0.383

Isoelectric point : 10.778

Charge (pH 7) : 6.8403

Aromaticity : 0.222

Molar extinction coefficient (cysteine, cystine): (5500, 5500)

Hydrophobic/hydrophilic ratio : 1.25

hydrophobic moment : 1.2282

Missing amino acid : C,R,Q,T,M,E,S,D,Y,N,V,G

Most occurring amino acid : K

Most occurring amino acid frequency : 7

Least occurring amino acid : W

Least occurring amino acid frequency : 1

Structural Information

3D structure :

Secondary structure fraction (Helix, Turn, Sheet): (0.6, 0.0, 0.4)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

Secondary Structure :

Method Prediction
GOR HHHHHHHHHHHHHHHHHH
Chou-Fasman (CF) HHHHHCCCHHHHHHHCCC
Neural Network (NN) HHHHHCHHHHHHHHHHHH
Joint/Consensus HHHHHCHHHHHHHHHHHH

Molecular Descriptors and ADMET Properties

Molecular Descriptors: Click here to download

ADMET Properties: Click here to download

Cross Referencing databases

Pubmed Id : 19957017

Uniprot : Not available

PDB : Not available

CancerPPD : Click here

ApIAPDB : Not available

CancerPPD2 ID : Not available

Reference

1 : Huang W, et al. Anti-melanoma activity of hybrid peptide P18 and its mechanism of action. Biotechnol Lett. 2010; 32:463-9. doi: 10.1007/s10529-009-0175-2

Literature

Paper title : Anti-melanoma activity of hybrid peptide P18 and its mechanism of action.

Doi : https://doi.org/10.1007/s10529-009-0175-2

Abstract : The anticancer properties and mechanism of action of a hybrid peptide -P18 were investigated. It had significant cytotoxic activity against human melanoma cells and low toxicity to normal NIH-3T3 cells. It also induced cell death via necrosis rather than classical apoptosis. The peptide targets the cells membrane, causing a sustained depolarization of transmembrane potential resulting in the cells swelling and bursting, thereby triggering cytolysis. P18 peptide initially binds to the melanoma cell membrane via electrostatic interaction, causing the cell membrane to rupture. The effect may be mediated by the amphiphilic alpha-helical structure of P18 peptide, coupled with changes in ion channels and an increase in plasma membrane permeability that eventually leads to melanoma cell death.